The abstract submission system is now open
Abstract submission deadlines
Deadline |
Date and time |
|---|---|
|
Tuesday, 11 February 2025, 21:00 CET (Central European Time) |
|
Tuesday, 15 April 2025, 21:00 CEST (Central European Summer Time)
A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline 11 February 2025. |
Outcome notifications
Outcome notifications of regular abstracts are expected to be made available to first authors and submitters by mid-March 2025.
Outcome notifications of accepted full LBAs are expected to be made available to first authors and submitters by end-April 2025.
Information for presenters
Detailed instructions for the preparation of slide presentations and/or posters will be made available by mid-March in the section “Information for Presenters”.
Abstract submission categories
- Biomarkers and translational research and precision medicine
- Early breast cancer: Surgery and radiotherapy
- Early breast cancer: Systemic treatments
- Early detection, hereditary breast cancer and prevention
- Metastatic breast cancer
- Supportive care and survivorship
- Miscellaneous
Late-breaking abstracts
Late-breaking abstracts may be submitted for high quality, new research findings from prospective interventional clinical trials or observational series (large real-world data sets) or novel technologies with major implications for clinical practice and/or understanding and targeting of disease processes.
The final late-breaking abstract deadline of 15 April 2025 is under no circumstances to be considered as an extension of the general submission deadline (11 February 2025).
Trial in Progress abstracts
Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to ESMO Breast Cancer 2025.
It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis.
Presentation and publication of accepted abstracts
The Breast Cancer 2025 Scientific Committee will select abstracts for presentation during the Congress and determine the format of the presentations from the following possibilities:
- Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
- Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
- Poster – Display session for review, discussion and questions. The presenting authors must be available for Q&A to represent their work.
All accepted abstracts, including Late-breaking, will be published online in the ESMO Breast Cancer 2025 Abstract Book, a supplement to the official ESMO journal, ESMO Open.
Publication schedule of accepted abstracts
Abstracts accepted for presentation during the ESMO Breast Cancer 2025 will be released online according to a schedule which will be available on the ESMO website in due course.
ESMO Merit Travel Grant
A restricted number of ESMO Merit Travel Grants to the ESMO Breast Cancer 2025 are available, upon application, to first author (= presenter) who submit abstracts considered to be deserving of recognition. Candidates must be ESMO Members under the age of 40. Selection will be made by the ESMO Breast Cancer 2025 Scientific Committee on a competitive basis from among the accepted abstracts.